Sankyo, KAI in cardiac pact | Chemical & Engineering News
Volume 84 Issue 3 | p. 16 | Concentrates
Issue Date: January 16, 2006

Sankyo, KAI in cardiac pact

Department: Business

Daiichi Sankyo and KAI Pharmaceuticals have formed a licensing agreement under which the Japanese firm will obtain development rights to KAI-9803, a cardiovascular drug candidate in Phase II clinical trials. Sankyo will pay KAI $20 million and milestone payments of up to $300 million. KAI may receive $20 million from Sankyo in research support over five years to identify new compounds, routes of administration, and indications for cardiovascular therapies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment